VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2022 | AZ257: Novel dopamine transporter receptor for the treatment of MS

Mirla Avila, MD, Texas Tech University Health Sciences Center, Lubbock, TX, discusses a novel dopamine transporter receptor, AZ257, which has been investigated in mouse models of multiple sclerosis (MS). The molecule has been found to have good penetrance of the blood-brain barrier and an anti-inflammatory effect. It was compared against the steroid methylprednisolone (SoluMedrol) in mouse models and was found to have a similar level of anti-inflammatory effect. However, AZ257 was reported to have a greater effect on reactive astrocytes than methylprednisolone. Dr Avila explains how these early results are promising but further research is needed, including larger trials and a greater understanding of the underlying biological mechanisms. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.